Actively Recruiting

Phase 2
Age: 0 - 55Years
All Genders
Healthy Volunteers
NCT06872333

Allo HSCT for High Risk Hemoglobinopathies

Led by Masonic Cancer Center, University of Minnesota · Updated on 2026-03-12

62

Participants Needed

1

Research Sites

393 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

CONDITIONS

Official Title

Allo HSCT for High Risk Hemoglobinopathies

Who Can Participate

Age: 0 - 55Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of sickle cell disease (SCD)
  • SCD patients with a fully matched sibling donor regardless of symptom severity
  • Transfusion dependent alpha- or beta-thalassemia
  • Diagnosis of Diamond Blackfan anemia
  • Other non-malignant hematologic disorders
  • Karnofsky performance score of 60% or higher or Lansky play score of 60 or higher
  • Patients with lower performance scores may be considered by study team evaluation
  • Sexually active persons of childbearing potential or those with partners of childbearing potential must agree to use highly effective contraception during treatment and for at least 4 months after transplant
Not Eligible

You will not qualify if you...

  • Pregnant, breastfeeding, or intending to become pregnant during the study
  • Persons of childbearing potential must have a negative pregnancy test within 7 days before starting treatment
  • HIV positive status
  • Active, uncontrolled infection; stable or improving infection after 1 week of appropriate therapy (4 weeks for fungal infections) allowed
  • Known allergy to any study components
  • Psychiatric illness or social situations limiting compliance with study requirements
  • Other illnesses or medical issues judged by the investigator to exclude patient from the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Masonic Cancer Center

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

Loading map...

Research Team

A

Ashish Gupta, MBBS, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here